Overview

Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The study focusses on the evaluation of safety and tolerability of the XC8. The design of the study involves sequential dosing of cohorts (group of volunteers), taking increasing doses of the product after receiving conclusion and recommendation for further continuation of the study from the Dose Escalation Committee.
Phase:
Phase 1
Details
Lead Sponsor:
EURRUS Biotech GmbH
Treatments:
Glutarimide
Histamine
Histamine phosphate